News
ABBV
263.29
-1.12%
-2.99
If You Invested $1000 In AbbVie Stock 10 Years Ago, You Would Have This Much Today
Benzinga · 8h ago
Defensive Dividends: 3 Companies Investors Can Rely On
NASDAQ · 12h ago
UnitedHealth, AbbVie And A Health Care Stock On CNBC’s ‘Final Trades’
Benzinga · 16h ago
AbbVie Partners With Valkai To Advance AI-powered Clinical Research
NASDAQ · 17h ago
Johnson & Johnson: Strong Catalysts, But I'm Staying At Hold
Seeking Alpha · 17h ago
AbbVie And Valkai Collaborate To Accelerate Pace Of Scientific Innovation's Reach To Patients
Benzinga · 17h ago
AbbVie partners with Valkai to apply advanced AI across clinical development
TipRanks · 18h ago
AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development
PR Newswire · 18h ago
Ginkgo Bioworks, Apheris announce kick off of Antibody Developability Consortium
TipRanks · 18h ago
Citi Keeps Their Hold Rating on AbbVie (ABBV)
TipRanks · 20h ago
AbbVie price target raised to $289 from $282 at BofA
TipRanks · 20h ago
Analysts’ Top Healthcare Picks: AbbVie (ABBV), Quantum-Si (QSI)
TipRanks · 20h ago
Pfizer: Growth Portfolio And Cost Cuts Support A Buy Through The LOE Trough
Seeking Alpha · 1d ago
The Zacks Analyst Blog Highlights Alphabet, Mastercard, AbbVie, Perma-Pipe and ImmuCell
NASDAQ · 1d ago
Should FDA Approval Require Action From AbbVie (ABBV) Investors?
Simply Wall St · 1d ago
Top Research Reports for Alphabet, Mastercard & AbbVie
NASDAQ · 1d ago
AbbVie’s New Parkinson’s Pill Could Become a Billion-Dollar Drug, Analyst Says
Benzinga · 1d ago
Analysts Are Bullish on Top Healthcare Stocks: Medicinova (MNOV), AbbVie (ABBV)
TipRanks · 1d ago
8 Of 11 Sectors Fall In Monday Trading As Defensives Lead
Benzinga · 1d ago
AbbVie Gets FDA OK of Juvmo for Parkinson's Disease
Dow Jones · 1d ago
More
Webull provides a variety of real-time ABBV stock news. You can receive the latest news about Abbvie Inc through multiple platforms. This information may help you make smarter investment decisions.
About ABBV
AbbVie Inc. is a global, diversified, research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. The aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Duodopa is a levodopa-carbidopa intestinal gel for the treatment of Parkinson's disease. Eye care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, and Restasis. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its pipeline also includes zumilokibart and APG273.